Behavioral modifications like goal setting could lead to greater weight loss on tirzepatide
· Medical Xpressedited by Sadie Harley, reviewed by Robert Egan
Sadie Harley
Scientific Editor
Meet our editorial team
Behind our editorial process
Robert Egan
Associate Editor
Meet our editorial team
Behind our editorial process Editors' notes
This article has been reviewed according to Science X's editorial process and policies. Editors have highlighted the following attributes while ensuring the content's credibility:
fact-checked
trusted source
proofread
The GIST Add as preferred source
One of the largest real-world studies of people taking GLP-1 medications found women, those without pre-existing conditions such as type 2 diabetes and high blood pressure, and behavioral factors such as previously setting a weight goal were the best predictors of total weight loss, according to a study presented at ENDO 2026, the Endocrine Society's annual meeting in Chicago.
The scientists believe the findings could help doctors personalize treatment options for weight management.
The research was a collaborative effort between Voy (Menwell Ltd.), a digital health service based in London, United Kingdom, and the Predictive Medicine Group at Boston Children's Hospital and Harvard Medical School in Boston.
The study took place from February 2024 through November 2025 and involved more than 80,000 adults using tirzepatide, a medication sold commercially as Mounjaro and Zepbound. The scientists designed the study to find out why the amount of weight individuals lost tended to vary significantly.
"It is one of the largest real-world studies of tirzepatide to date and is the first to identify behavioral and clinical predictors that anticipate who will respond best to the medication," said Hans Johnson, M.B.Ch.B., M.Res., F.R.S.P.H., research lead in the Department of Clinical Research and Innovation at Voy.
Johnson and his colleagues used Cox proportional hazards models to determine the time needed to achieve 20% total body weight loss. They also employed multivariate mixed models to find associations between baseline clinical, demographic and behavioral variables and weight loss trajectories over 12 months.
The team found that women tended to lose more weight on tirzepatide than men and that pre-existing conditions such as type 2 diabetes, high cholesterol, hypertension, metabolic liver disease and obstructive sleep apnea were associated with less weight loss.
Based on the mixed models, the researchers established that behavioral factors, like setting a personal weight goal or having previously attempted structured diets, were associated with significantly greater weight loss. In contrast, participants who lacked the self-motivation to lose weight experienced minimal weight loss on the medication.
"These findings could help physicians better counsel patients about realistic expectations and tailor their support to the needs of each patient," Johnson said. "For example, doctors could ensure patients with motivational barriers to losing weight receive additional behavioral interventions alongside their medication."
Key medical concepts
TirzepatideBehavior TherapyDiabetes Type 2High Blood Pressure
Clinical categories
EndocrinologyWeight managementClinical pharmacology Provided by The Endocrine Society Who's behind this story?
Sadie Harley
BSc Life Sciences & Ecology. Microbiology lab background with pharmaceutical news experience in oil, gas, and renewable industries. Full profile →
Robert Egan
Bachelor's in mathematical biology, Master's in creative writing. Well-traveled with unique perspectives on science and language. Full profile →
Citation: Behavioral modifications like goal setting could lead to greater weight loss on tirzepatide (2026, June 15) retrieved 15 June 2026 from https://medicalxpress.com/news/2026-06-behavioral-modifications-goal-greater-weight.html This document is subject to copyright. Apart from any fair dealing for the purpose of private study or research, no part may be reproduced without the written permission. The content is provided for information purposes only.